CapIQ
Source: S&P Capital IQ consensus via Xpressfeed · Generated 2026-07-22.
Consensus for EPAM is being marked up on earnings even as the top line is trimmed: over the past 180 days FY2028 normalized EPS estimates rose about 7% while FY2028 revenue was cut roughly 5%, a margin-led upgrade. The company has beaten both revenue and normalized-EPS consensus in every one of the last eight quarters, with EPS the larger of the two surprises. Coverage stays deep through FY2027 but thins sharply in the outer years.
FY2028 EPS estimates up ~7% over 180 days as revenue is cut ~5%
FY2027 shows the same split — EPS higher, revenue lower over six months — while the last 30 days were essentially flat for both lines.
Currency: USD · Scale: money in millions, absolute · Point-in-time consensus; Δ90d is Now versus 90d.
| Metric | FY | 180d | 90d | 30d | Now | Δ90d |
|---|---|---|---|---|---|---|
| EPS (normalized) | FY2027 | $13.90 | $13.92 | $14.17 | $14.13 | +1.6% |
| EPS (normalized) | FY2028 | $14.32 | $15.17 | $15.29 | $15.26 | +0.6% |
| Revenue | FY2027 | $6.32bn | $6.20bn | $6.07bn | $6.05bn | -2.4% |
| Revenue | FY2028 | $6.77bn | $6.65bn | $6.46bn | $6.44bn | -3.1% |
Normalized EPS compounding faster than revenue through FY2028
Currency: USD · Scale: money in millions, absolute · YoY uses the prior fiscal year from the feed; analyst count and range use the first displayed period.
| Metric | FY2026E | FY2027E | FY2028E | YoY | Analysts | Low / high |
|---|---|---|---|---|---|---|
| Revenue | $5.72bn | $6.05bn | $6.44bn | +4.9% | 19 | $5.67bn / $5.77bn |
| EPS (normalized) | $13.05 | $14.13 | $15.26 | +13.4% | 19 | $12.82 / $13.15 |
Eight straight quarters beating both revenue and EPS consensus
Normalized-EPS surprises have generally run larger than revenue surprises, consistent with sandbagged earnings guidance rather than fair-value guiding.
Current sequences by metric: Revenue: 8 consecutive beats; EPS (normalized): 8 consecutive beats.
Currency: USD · Scale: money in millions, absolute · Consensus is captured before each actual first became effective.
| Quarter | Metric | Consensus | Actual | Surprise | Outcome |
|---|---|---|---|---|---|
| Q1 FY2026 | Revenue | $1.39bn | $1.40bn | +0.4% | Beat |
| Q1 FY2026 | EPS (normalized) | $2.75 | $2.86 | +3.8% | Beat |
| Q4 FY2025 | Revenue | $1.39bn | $1.41bn | +1.2% | Beat |
| Q4 FY2025 | EPS (normalized) | $3.16 | $3.26 | +3.2% | Beat |
| Q3 FY2025 | Revenue | $1.38bn | $1.39bn | +1.4% | Beat |
| Q3 FY2025 | EPS (normalized) | $3.03 | $3.08 | +1.7% | Beat |
| Q2 FY2025 | Revenue | $1.33bn | $1.35bn | +1.5% | Beat |
| Q2 FY2025 | EPS (normalized) | $2.61 | $2.77 | +6.0% | Beat |
| Q1 FY2025 | Revenue | $1.28bn | $1.30bn | +1.5% | Beat |
| Q1 FY2025 | EPS (normalized) | $2.27 | $2.41 | +6.1% | Beat |
| Q4 FY2024 | Revenue | $1.21bn | $1.25bn | +2.9% | Beat |
| Q4 FY2024 | EPS (normalized) | $2.75 | $2.84 | +3.1% | Beat |
| Q3 FY2024 | Revenue | $1.15bn | $1.17bn | +1.4% | Beat |
| Q3 FY2024 | EPS (normalized) | $2.70 | $3.12 | +15.6% | Beat |
| Q2 FY2024 | Revenue | $1.14bn | $1.15bn | +0.6% | Beat |
| Q2 FY2024 | EPS (normalized) | $2.26 | $2.45 | +8.5% | Beat |
Analysts split on outer-year earnings: FY2028 EPS spans $13.86–$16.55
The FY2027 band is tighter and rests on 19 analysts; FY2028's wider range reflects both real disagreement and fewer contributors, and a single analyst covers FY2029.
Currency: USD · Scale: money in millions, absolute · Spread/mean is absolute high-low divided by absolute mean.
| Metric | Period | Mean | Low–high | Spread/mean | Analysts |
|---|---|---|---|---|---|
| EPS (normalized) | FY2027E | $14.13 | $13.08–$14.72 | 11.6% | 19 |
| EPS (normalized) | FY2028E | $15.26 | $13.86–$16.55 | 17.6% | 11 |
Wide target spread ($83–$235) under a balanced buy/hold book
Currency: USD · Scale: money in millions, absolute · Analyst counts shown explicitly.
| Street view | Reading | Analysts |
|---|---|---|
| Recommendation mix | Buy 8, Outperform 3, Hold 8, Underperform 0, Sell 0 | 19 |
| Consensus score | 2.00 | 19 |
| Target price | mean $135.9; median $131.0; high $235.0; low $83.00 | 17 |